These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 19192027)

  • 1. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial.
    Svendsen M; Rissanen A; Richelsen B; Rössner S; Hansson F; Tonstad S
    Obesity (Silver Spring); 2008 Feb; 16(2):327-33. PubMed ID: 18239640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
    MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC
    Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
    Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP
    Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
    Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band.
    Zoss I; Piec G; Horber FF
    Obes Surg; 2002 Feb; 12(1):113-7. PubMed ID: 11868286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of orlistat on fecal fat, fecal biliary acids, and colonic cell proliferation in obese subjects.
    Ahnen DJ; Guerciolini R; Hauptman J; Blotner S; Woods CJ; Wargovich MJ
    Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1291-9. PubMed ID: 17920338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J; Lippl F; Klose G; Schusdziarra V
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
    Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
    Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat treatment of unconjugated hyperbilirubinemia in Crigler-Najjar disease: a randomized controlled trial.
    Hafkamp AM; Nelisse-Haak R; Sinaasappel M; Oude Elferink RP; Verkade HJ
    Pediatr Res; 2007 Dec; 62(6):725-30. PubMed ID: 17957158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.